Cargando…

Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study

BACKGROUND: Fimasartan is a novel angiotensin II receptor blocker. Fimasartan is mainly eliminated via biliary excretion, and its urinary elimination is less than 3%. OBJECTIVE: Based on guidance from the United States Food and Drug Administration, a reduced pharmacokinetic (PK) study was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Seokuee, Lee, Jongtae, Shin, Donghoon, Lim, Kyoung Soo, Kim, Yon Su, Jang, In-Jin, Yu, Kyung-Sang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199969/ https://www.ncbi.nlm.nih.gov/pubmed/25336916 http://dx.doi.org/10.2147/DDDT.S68784

Ejemplares similares

Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
por: Kang, Woo Youl, et al.
Publicado: (2018)

Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers
por: Choi, Yewon, et al.
Publicado: (2018)

The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
por: Gu, Namyi, et al.
Publicado: (2016)

Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy
por: Rhee, Moo-Yong, et al.
Publicado: (2015)

Pharmacokinetic comparison between a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects
por: Jung, Jihyun, et al.
Publicado: (2021)

Predictive performance of gentamicin dosing nomograms
por: Lee, Jieon, et al.
Publicado: (2014)

A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers
por: Kang, Woo Youl, et al.
Publicado: (2020)

Fimasartan attenuates renal ischemia-reperfusion injury by modulating inflammation-related apoptosis
por: Cho, Jang-Hee, et al.
Publicado: (2018)

Fimasartan for Remodeling after Myocardial Infarction
por: Lim, Byung-Kwan, et al.
Publicado: (2019)

Pharmacokinetic comparison between fixed-dose combination of fimasartan/amlodipine 60/10 mg and the corresponding loose combination through partial replicated crossover study in healthy subjects
por: Yang, Eunsol, et al.
Publicado: (2019)

Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain
por: Kim, Chi Kyung, et al.
Publicado: (2015)

Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians
por: Lee, Jieon, et al.
Publicado: (2018)

Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects
por: Oh, Minkyung, et al.
Publicado: (2018)

Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension
por: Shin, Mi-Seung, et al.
Publicado: (2016)

Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
por: Hong, Keun-Sik, et al.
Publicado: (2021)

A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy
por: Jeon, Eun-Seok, et al.
Publicado: (2022)

Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved In Situ Absorption Method in Rats
por: Kim, Tae Hwan, et al.
Publicado: (2018)

Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial
por: Kang, Min-gu, et al.
Publicado: (2019)

Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study): An Open-Label Observational Study
por: Park, Jeong Bae, et al.
Publicado: (2013)

Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats
por: Kim, Tae Hwan, et al.
Publicado: (2016)

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
por: Wiebe, Sabrina, et al.
Publicado: (2016)

Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study
por: Smith, William B, et al.
Publicado: (2012)

Pharmacokinetic and Safety Profiles of a Fixed‐Dose Combination of Amlodipine, Valsartan, and Atorvastatin: A 3‐Period Replicate Crossover Study
por: Kim, Seokuee, et al.
Publicado: (2019)

Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H: quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials
por: Kim, Seokuee, et al.
Publicado: (2017)

Comparison of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2018)

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2017)

Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension
por: Kim, Song-Yi, et al.
Publicado: (2016)

24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension
por: Lee, Hae-Young, et al.
Publicado: (2017)

Comparison of the Pharmacokinetics of Highly Variable Drugs in Healthy Subjects Using a Partial Replicated Crossover Study: A Fixed-Dose Combination of Fimasartan 120 mg and Atorvastatin 40 mg versus Separate Tablets
por: Hwang, Jun Gi, et al.
Publicado: (2020)

Fimasartan: A new armament to fight hypertension
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Decreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysis
por: Kim, Choon OK, et al.
Publicado: (2017)

Dose selection method for pharmacokinetic study in hemodialysis patients using a subpharmacological dose: oseltamivir as a model drug
por: Kim, Dong Ki, et al.
Publicado: (2014)

Cardioprotective Effect of Fimasartan, a New Angiotensin Receptor Blocker, in a Porcine Model of Acute Myocardial Infarction
por: Sim, Doo Sun, et al.
Publicado: (2015)

The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics
por: Kim, Changsoo, et al.
Publicado: (2014)

Gender-specific differences in the incidence of microalbuminuria in metabolic syndrome patients after treatment with fimasartan: The K-MetS study
por: Park, Jeong Bae, et al.
Publicado: (2017)

Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO(®) (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers
por: Choi, YoonJung, et al.
Publicado: (2015)

Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers
por: Kim, Hyungsub, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study
por: Yang, Eunsol, et al.
Publicado: (2021)

Fimasartan, a Novel Angiotensin-Receptor Blocker, Protects against Renal Inflammation and Fibrosis in Mice with Unilateral Ureteral Obstruction: the Possible Role of Nrf2
por: Kim, Soojeong, et al.
Publicado: (2015)

Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study)
por: Chung, Woo-Baek, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a2m238cbqaj2sbkucl52qdfk1u